"The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approv"...
Prophylaxis of Gout Flares
Treatment of Gout Flares
The most common adverse reactions reported in the clinical trial with COLCRYS for treatment of gout flares were diarrhea (23%) and pharyngolaryngeal pain (3%).
Gastrointestinal tract adverse effects are the most frequent side effects in patients initiating COLCRYS, usually presenting within 24 hours, and occurring in up to 20% of patients given therapeutic doses. Typical symptoms include cramping, nausea, diarrhea, abdominal pain and vomiting. These events should be viewed as dose-limiting if severe, as they can herald the onset of more significant toxicity.
Clinical Trials Experience In Gout
Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.
In a randomized, double-blind, placebo-controlled trial in patients with a gout flare, gastrointestinal adverse reactions occurred in 26% of patients using the recommended dose (1.8 mg over one hour) of COLCRYS compared to 77% of patients taking a nonrecommended high dose (4.8 mg over six hours) of colchicine and 20% of patients taking placebo. Diarrhea was the most commonly reported drug-related gastrointestinal adverse event. As shown in Table 3, diarrhea is associated with COLCRYS treatment. Diarrhea was more likely to occur in patients taking the high-dose regimen than the lowdose regimen. Severe diarrhea occurred in 19% and vomiting occurred in 17% of patients taking the nonrecommended high-dose colchicine regimen but did not occur in the recommended low-dose COLCRYS regimen.
Table 3: Number (%) of Patients with at Least One
Drug-Related Treatment-Emergent Adverse Event with an Incidence of ≥ 2% of
Patients in Any Treatment Group
|MedDRA System Organ Class
MedDRA Preferred Term
|Number of Patients with at Least One Drug-Related TEAE||40 (77)||27 (37)||16 (27)|
|Gastrointestinal Disorders||40 (77)||19 (26)||12 (20)|
|Diarrhea||40 (77)||17 (23)||8 (14)|
|Nausea||9 (17)||3 (4)||3 (5)|
|Abdominal Discomfort||0||0||2 (3)|
|General Disorders and Administration Site Conditions||4 (8)||1 (1)||1 (2)|
|Fatigue||2 (4)||1 (1)||1 (2)|
|Metabolic and Nutrition Disorders||0||3 (4)||2 (3)|
|Gout||0||3 (4)||1 (2)|
|Nervous System Disorders||1 (2)||1 (1.4)||2 (3)|
|Headache||1 (2)||1 (1)||2 (3)|
|Respiratory Thoracic Mediastinal Disorders||1 (2)||2 (3)||0|
|Pharyngolaryngeal Pain||1 (2)||2 (3)||0|
Serious toxic manifestations associated with colchicine include myelosuppression, disseminated intravascular coagulation and injury to cells in the renal, hepatic, circulatory and central nervous systems.
These most often occur with excessive accumulation or overdosage [see OVERDOSAGE].
The following adverse reactions have been reported with colchicine. These have been generally reversible upon temporarily interrupting treatment or lowering the dose of colchicine.
Neurological: sensory motor neuropathy
Dermatological: alopecia, maculopapular rash, purpura, rash
Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting
Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia
Hepatobiliary: elevated AST, elevated ALT
Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis
Reproductive: azoospermia, oligospermia
Read the Colcrys (colchicine tablets) Side Effects Center for a complete guide to possible side effects
COLCRYS (colchicine) is a substrate of the efflux transporter P-glycoprotein (P-gp). Of the cytochrome P450 enzymes tested, CYP3A4 was mainly involved in the metabolism of colchicine. If COLCRYS is administered with drugs that inhibit P-gp, most of which also inhibit CYP3A4, increased concentrations of colchicine are likely. Fatal drug interactions have been reported.
Physicians should ensure that patients are suitable candidates for treatment with COLCRYS and remain alert for signs and symptoms of toxicities related to increased colchicine exposure as a result of a drug interaction. Signs and symptoms of COLCRYS toxicity should be evaluated promptly and, if toxicity is suspected, COLCRYS should be discontinued immediately.
Table 4 provides recommendations as a result of other potentially significant drug interactions. Table 1 provides recommendations for strong and moderate CYP3A4 inhibitors and P-gp inhibitors.
Table 4: Other Potentially Significant Drug
|Concomitant Drug Class or Food||Noted or Anticipated Outcome||Clinical Comment|
|HMG-Co A Reductase Inhibitors: atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin||Pharmacokinetic and/or pharmacodynamic interaction: the addition of one drug to a stable longterm regimen of the other has||Weigh the potential benefits and risks and carefully monitor patients for any signs or symptoms of muscle pain,|
|Other Lipid-Lowering Drugs: fibrates, gemfibrozil||resulted in myopathy and rhabdomyolysis (including a fatality)||tenderness, or weakness, particularly during initial therapy; monitoring CPK|
|Digitalis Glycosides: digoxin||P-gp substrate; rhabdomyolysis has been reported||(creatine phosphokinase) will not necessarily prevent the occurrence of severe myopathy.|
Drug Abuse And Dependence
Tolerance, abuse or dependence with colchicine has not been reported.
Read the Colcrys Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 1/5/2016
Additional Colcrys Information
Colcrys - User Reviews
Colcrys User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.